366 related articles for article (PubMed ID: 31425551)
21. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
22. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
Gupta V; Dixit NM
PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
[TBL] [Abstract][Full Text] [Related]
23. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
24. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
[TBL] [Abstract][Full Text] [Related]
25. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
26. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
27. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
[TBL] [Abstract][Full Text] [Related]
29. A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection.
Mann JFS; Pankrac J; Klein K; McKay PF; King DFL; Gibson R; Wijewardhana CN; Pawa R; Meyerowitz J; Gao Y; Canaday DH; Avino M; Poon AFY; Foster C; Fidler S; Shattock RJ; Arts EJ
EBioMedicine; 2020 Sep; 59():102853. PubMed ID: 32654992
[TBL] [Abstract][Full Text] [Related]
30. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
31. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
32. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
[TBL] [Abstract][Full Text] [Related]
33. Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.
Gálvez C; Grau-Expósito J; Urrea V; Clotet B; Falcó V; Buzón MJ; Martinez-Picado J
mBio; 2021 Dec; 12(6):e0307821. PubMed ID: 34844430
[TBL] [Abstract][Full Text] [Related]
34. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
35. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
[TBL] [Abstract][Full Text] [Related]
36. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
[TBL] [Abstract][Full Text] [Related]
38. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
39. Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen.
Liu H; Hu PW; Dubrulle J; Stossi F; Nikolai BC; Mancini MA; Rice AP
PLoS One; 2021; 16(4):e0244771. PubMed ID: 33914760
[TBL] [Abstract][Full Text] [Related]
40. High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.
Yucha RW; Hobbs KS; Hanhauser E; Hogan LE; Nieves W; Ozen MO; Inci F; York V; Gibson EA; Thanh C; Shafiee H; El Assal R; Kiselinova M; Robles YP; Bae H; Leadabrand KS; Wang S; Deeks SG; Kuritzkes DR; Demirci U; Henrich TJ
EBioMedicine; 2017 Jun; 20():217-229. PubMed ID: 28529033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]